Last reviewed · How we verify
Sham Avastin Intravitreal Injection
Sham Avastin Intravitreal Injection is a Small molecule drug developed by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. It is currently in Phase 3 development for Sham control arm in phase 3 trials (not a therapeutic indication). Also known as: Sham.
This is a sham (placebo) intravitreal injection used as a control in clinical trials, containing no active pharmaceutical ingredient.
This is a sham (placebo) intravitreal injection used as a control in clinical trials, containing no active pharmaceutical ingredient. Used for Sham control arm in phase 3 trials (not a therapeutic indication).
At a glance
| Generic name | Sham Avastin Intravitreal Injection |
|---|---|
| Also known as | Sham |
| Sponsor | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Sham Avastin refers to a placebo comparator in phase 3 clinical trials evaluating intravitreal bevacizumab (Avastin). The sham injection mimics the administration procedure of the active drug but delivers an inert substance, allowing researchers to isolate the true therapeutic effect of bevacizumab from procedural and expectation effects in ophthalmologic conditions.
Approved indications
- Sham control arm in phase 3 trials (not a therapeutic indication)
Common side effects
Key clinical trials
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (PHASE3)
- Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy (PHASE4)
- Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia (PHASE3)
- Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema (PHASE2, PHASE3)
- Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (PHASE3)
- Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema (PHASE2, PHASE3)
- Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema (PHASE2)
- Avastin for PDR (Proliferative Diabetic Retinopathy) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sham Avastin Intravitreal Injection CI brief — competitive landscape report
- Sham Avastin Intravitreal Injection updates RSS · CI watch RSS
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA portfolio CI
Frequently asked questions about Sham Avastin Intravitreal Injection
What is Sham Avastin Intravitreal Injection?
How does Sham Avastin Intravitreal Injection work?
What is Sham Avastin Intravitreal Injection used for?
Who makes Sham Avastin Intravitreal Injection?
Is Sham Avastin Intravitreal Injection also known as anything else?
What development phase is Sham Avastin Intravitreal Injection in?
Related
- Manufacturer: Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Sham control arm in phase 3 trials (not a therapeutic indication)
- Also known as: Sham
- Compare: Sham Avastin Intravitreal Injection vs similar drugs
- Pricing: Sham Avastin Intravitreal Injection cost, discount & access